Ted White - 05 Jul 2022 Form 4/A - Amendment Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
President and CEO, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
VRCA
Transactions as of
05 Jul 2022
Net transactions value
+$15,750
Form type
4/A - Amendment
Filing time
21 Feb 2023, 15:08:37 UTC
Date Of Original Report
05 Jul 2022
Previous filing
25 Feb 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRCA Common Stock Purchase $15,750 +7,500 +34% $2.10 29,466 05 Jul 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original Form 4 inadvertently listed the incorrect number of shares purchased by the Reporting Person. This represents the correct number of shares.